What is ELOX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ELOX?

P/E (TTM) is n/a and 52-week range is n/a when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ELOX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ELOX?

The company profile lists revenue (TTM) near $160K, net income (TTM) near -$618M, EPS (TTM) near -$7.06 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Eloxx Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 4M shares outstanding, ISIN US29014R2022 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Eloxx Pharmaceuticals Inc

$ELOX

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Employees

Website

www.eloxxpharma.com/

IPO

2012-11-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)